

Electronic Acknowledgement Receipt

EFS ID:	7130023
Application Number:	09423698
International Application Number:	
Confirmation Number:	7060
Title of Invention:	MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER
First Named Inventor/Applicant Name:	ODILE LEROY
Customer Number:	20306
Filer:	Michael S. Greenfield
Filer Authorized By:	
Attorney Docket Number:	99-849-A
Receipt Date:	03-MAR-2010
Filing Date:	10-FEB-2000
Time Stamp:	18:53:29
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$3160
RAM confirmation Number	8804
Deposit Account	132490
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Extension of Time	99-849-A_5mo_EOT.pdf	145526	no	1
			c659f885297cff9d424ec155f81780bd353ac5b0		

Warnings:

Information:

2		99-849-A_ResponseAfterFinal_3-3-10.pdf	3442601	yes	29
			fc0c95dc9e499e561af62bba7c5563f294994a8c		

Multipart Description/PDF files in .zip description

	Document Description	Start	End
	Amendment After Final	1	1
	Amendment Copy Claims/Response to Suggested Claims	2	5
	Applicant Arguments/Remarks Made in an Amendment	6	26
	Miscellaneous Incoming Letter	27	29

Warnings:

Information:

3	Rule 130, 131 or 132 Affidavits	99-849-A_Rule132_Schulz_Declaration.pdf	864773	no	11
			4cb2cbd1831df15159d717f850558498765dd80e		

Warnings:

Information:

4	Foreign Reference	WO03051392.pdf	1746985	no	47
			6b0ae50c6677244a25ce0a1a3d2631ef2b433d6b		

Warnings:

Information:

5	NPL Documents	Steinhoff_RandomizedComparison_P368_372.pdf	490312	no	5
			2974bbf1cfa86c406d54fe27d80070b4065f6a52		

Warnings:

Information:

6	NPL Documents	Chiu_SafetyAndImmunogenicity_G71.pdf	83222	no	1
			e3589813dc310d142f2bd38477bf59976a78e51f		
Warnings:					
Information:					
7	NPL Documents	Daum_Immunogenicity_G65.pdf	89607	no	1
			a528b87431f0404c792d2db8452525f411c43b4a		
Warnings:					
Information:					
8	NPL Documents	OBrien_ImmunologicPriming.pdf	631945	no	6
			89bb920a543fd58a40b50bea6bafb45ff853ae50		
Warnings:					
Information:					
9	NPL Documents	Rennels_Abstract1082.pdf	144394	no	1
			531b72453673b18b4015fe15761155ac92581166		
Warnings:					
Information:					
10	NPL Documents	Shelly_Comparison.pdf	660054	no	6
			f279049961b15a5ff761834d0450edf34897eb34		
Warnings:					
Information:					
11	NPL Documents	Kennedy_G88_P236_ImmunologicResponse.pdf	100213	no	1
			c19e1049dff7e53ef1cd566f26d50453304257542		
Warnings:					
Information:					
12	NPL Documents	Nieminen_Mucosal.pdf	93149	no	1
			24c27e4f63af41d6f3732c10e2a917b1158c634d		
Warnings:					
Information:					
13	NPL Documents	Portier_SerumAntibody.pdf	81461	no	1
			7eae48952976e050f2908f7f4a5b3606708b7e9		
Warnings:					
Information:					
14	NPL Documents	Keyserling_Immunogenicity.pdf	75456	no	1
			dac218bf3f613caac7d0de744ff580515a0a295a		
Warnings:					
Information:					

15	NPL Documents	Kennedy_ImmunologicResponseToLicensed.pdf	44844	no	1
			ecd1fa417900f19195328717fa53e8bc3f1823bb		
Warnings:					
Information:					
16	NPL Documents	Kayhty_Pneumococcal.pdf	522159	no	6
			288e51d7353b55bee2346808a9a5f631f605ef9a		
Warnings:					
Information:					
17	NPL Documents	Dagan_ReductionOfNasopharyngeal.pdf	741301	no	8
			e95bf526593feff28e9bb2460513ce71cd785864		
Warnings:					
Information:					
18	NPL Documents	Sood_CapsularPolysaccharide.pdf	634618	no	7
			62a93b78df2ae633be933db622ebcfa96eafed35		
Warnings:					
Information:					
19	NPL Documents	Sarnaik_StudiesOnPneumococcus.pdf	660898	no	6
			c76a6bb8f12314e1eb597a4b9110da29874e2e79		
Warnings:					
Information:					
20	NPL Documents	Andrew_PneumococcalVaccines.pdf	1244151	no	14
			2add4b59b9cfea4145a679a2d75bbb63adb5414f		
Warnings:					
Information:					
21	NPL Documents	Dagan_ReductionOfPneumococcal.pdf	538901	no	5
			9f864f8a0992875f815a4610e7657c0fb3b7e9ca		
Warnings:					
Information:					
22	NPL Documents	Lindberg_Recent_Trends.pdf	819314	no	13
			fa0650c6664a6c795c5f91d3dff6b19b99d00375		
Warnings:					
Information:					
23	NPL Documents	Greenberg_FactorsInfluencing_P121.pdf	184429	no	2
			b56cb6498637aabdd412df2cfb8ec44de89b86ca		
Warnings:					
Information:					

24	NPL Documents	Ahman_ImmunogenicityOfTetravalent_Abstracts.pdf	158624	no	2
			37bdfdaa07e7b26b0764771950bc4592792fabf9		
Warnings:					
Information:					
25	NPL Documents	Schutze_CarrierInduced_2319_2322.pdf	391774	no	4
			8c57fb3f4cb944664a08261ac11b9ab7a186935c		
Warnings:					
Information:					
26	NPL Documents	Develasco_MicrobiologicalReviews_P591_603.pdf	1447601	no	13
			781d084e7251844775133fe5e93b20b07f9b112c		
Warnings:					
Information:					
27	NPL Documents	Insel_P35_47.pdf	905553	no	13
			ec5dc03636ea9c9a18e41a3d9006a2975f2ef9ed		
Warnings:					
Information:					
28	NPL Documents	Galelli_P2397_2405.pdf	1039847	no	9
			c92f1db772780382f23b26e0c69c26c58e225d73		
Warnings:					
Information:					
29	NPL Documents	Barington_InfectionAndImmunity_P432_438.pdf	633047	no	7
			9b046568ce0372a4b883629bcf9dc55b56371aad		
Warnings:					
Information:					
30	NPL Documents	DiJohn_LancetP1415_1418.pdf	396920	no	4
			b7e2895a71b11782899fc0b5b8c4d0fca846d9e		
Warnings:					
Information:					
31	NPL Documents	Leclerc_P1343_1349.pdf	820572	no	7
			d70ac375977f3cb4f43d2f25aab9f0d09277d445		
Warnings:					
Information:					
32	NPL Documents	Clemens_AnnualsNewYorkAcademyOfScience_P255_266.pdf	875688	no	12
			a4bcbf019cb6a012d6ae9dcb0af24d24fb793b4e		
Warnings:					
Information:					

33	NPL Documents	Molrine_AnnalsOfInternalMedicine.pdf	745514	no	7
			eba8f78200c217be534d8c7892951d5c1d68d8cf		
Warnings:					
Information:					
34	NPL Documents	Anderson_1554_1559.pdf	418119	no	6
			31043e4c163333b0ade2824d70c99da23c1d4b21		
Warnings:					
Information:					
35	NPL Documents	Peeters_MethodsInMolecularMedicine_P111_133.pdf	1719822	no	23
			d139b34b0b3fe99ab271c0a29402ede5bd160887		
Warnings:					
Information:					
36	NPL Documents	Andre_CombinationVaccines_Jan1999.pdf	80121	no	2
			8236c3690da8b0da3867548f7f104916d5502b2b		
Warnings:					
Information:					
37	NPL Documents	Anderson_Immunol_P2464_2468.pdf	554691	no	5
			6973b20975be6e4d00fecf095f0e8ae0773a75ff		
Warnings:					
Information:					
38	NPL Documents	Butler_InfectDis_P885_889.pdf	435628	no	5
			1c4f1facd2b0088d186131dfb3f77557295ddb4c		
Warnings:					
Information:					
39	NPL Documents	Dagan_PediatrInfectDis_91_98.pdf	735035	no	8
			4ffc8abf7213383a27fb25873cf158c7edf4f81a		
Warnings:					
Information:					
40	NPL Documents	Ellis_Granoff_DevelopmentAndClinicalUses.pdf	357202	no	7
			51b546d876c4cbad90c008f1783ff3aa891f08f0		
Warnings:					
Information:					
41	NPL Documents	Eskola_Lancet_P1688_1692.pdf	467741	no	5
			6efea8423da6cb2a164934e1e13a87db9de78334		
Warnings:					
Information:					

42	NPL Documents	Todar_OnlineTextbook.pdf	1401315	no	18
			b9b17ae6f4d6afba7f61628a6e0beec2b8fe937		
Warnings:					
Information:					
43	NPL Documents	Svenson_Lindberg_ImmunolMeth_P323-335.pdf	875978	no	13
			c7f34a1ad9afeea065a5aaf3cf20734dcd347fd1		
Warnings:					
Information:					
44	NPL Documents	Svenson_Lindberg_P490_496.pdf	534599	no	7
			df8df886d5f7efc3ebeb7288ad238d243b6e1caa		
Warnings:					
Information:					
45	NPL Documents	Wuorimaa_InfectDis_P1211_1215.pdf	353590	no	5
			9c68c0d3cb781b5e6d3f803431e1dd7d3aab4a8d		
Warnings:					
Information:					
46	NPL Documents	Wuorimaa_Vaccine_P5328_5332.pdf	402888	no	5
			ed1cb6e0472b02f60a73fcd06e95d789f12e3f2f		
Warnings:					
Information:					
47	NPL Documents	Schneerson_InfectImmun_P582_591.pdf	1071210	no	11
			2c421cf70926a06dc3362855f03587a42e3b98ba		
Warnings:					
Information:					
48	NPL Documents	Cho_1995_ICAAC_172.pdf	56176	no	1
			818e129deb724bf3d6196e0317d2c293eb24f826		
Warnings:					
Information:					
49	NPL Documents	Kuo_Inflmm_P2706_2713.pdf	881695	no	8
			0d40aa4e73b659b3c8fcc86fcf58c81eacdc_d2c1		
Warnings:					
Information:					
50	NPL Documents	Eby_Pneumococcal_Conjugates_P119_123.pdf	350870	no	5
			031b4d9557551fdc30046db33900b158f8ab127c		
Warnings:					
Information:					

51	NPL Documents	Lindberg_PolysaccharideVaccines_P69_85.pdf	1128386 8fe23b1993b4d62f3db6883b43d6d226609a897b	no	17
Warnings:					
Information:					
52	Miscellaneous Incoming Letter	99-849-A_Transmittal.pdf	305168 29a5c70d72a2d1098b48070b4eb8249b7f3688ab	no	2
Warnings:					
Information:					
53	Request for Continued Examination (RCE)	99-849-A_RCE.pdf	922960 d7e39b66eddd8c6ef1a5608317eff43c8c33d0fe	no	3
Warnings:					
Information:					
54		99-849-A_Suppl_IDS-1.pdf	5821216 944cdba901ef1275a5e6d128810480f501b26217	yes	8
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Information Disclosure Statement (IDS) Filed (SB/08)		1	6	
	Miscellaneous Incoming Letter		7	8	
Warnings:					
Information:					
55	Fee Worksheet (PTO-875)	fee-info.pdf	32666 f4050f9ff7751795a3917dc8f8c1ac8f7524319	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			40362529		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.